<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>New daily persistent headache</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">New daily persistent headache</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">New daily persistent headache</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ivan Garza, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd J Schwedt, MD, MSCI</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Elizabeth Robertson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard P Goddeau, Jr, DO, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>New daily persistent headache (NDPH) is a type of chronic daily headache that begins one day and typically does not remit. Many patients can pinpoint the exact date their headache started. NDPH may occur spontaneously or after a systemic trigger such as infection or a stressful life event. For some patients, NDPH can be refractory to treatment and may endure for many years or even decades.</p><p>This topic will discuss NDPH. An overview of the causes of and evaluation for other types of chronic daily headache is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/3333.html" rel="external">"Chronic daily headache: Associated syndromes, evaluation, and management"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>The pathophysiology of NDPH is poorly understood. NDPH is characterized by a specific date of onset that may be associated with a triggering event, but pathophysiologic correlates are largely speculative.</p><p class="headingAnchor" id="H2272660768"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>The observation that headache onset can occur in relation to infection or flu-like illness suggests a possible microbial etiology. Several viral infections have been associated with NDPH in observational studies, including Epstein-Barr virus (EBV), herpes simplex virus (HSV), cytomegalovirus (CMV), dengue virus, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [<a href="#rid1">1-6</a>]. As examples, a case-control study found evidence of active EBV infection in 27 of 32 patients (85 percent) with NDPH compared with 8 of 32 controls (25 percent) [<a href="#rid7">7</a>]. In a retrospective analysis of 18 NDPH cases, evidence of recent infection with HSV was found in six patients and CMV in two, but no evidence of EBV was found [<a href="#rid2">2</a>]. Of note, the positive cases for HSV or CMV had been seen within 60 days of headache onset. An activated autoimmune response that may lead to persistent neurogenic inflammation has been hypothesized to account for NDPH [<a href="#rid8">8</a>], but the potential causal role of viral or other infection in the pathogenesis remains to be determined.</p><p class="headingAnchor" id="H27761526"><span class="h2">Triggers and risk factors</span><span class="headingEndMark"> — </span>Some reports have related the specified time of onset of NDPH with an environmental or situational trigger. Triggering factors most commonly identified with NDPH include [<a href="#rid1">1,9,10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Stressful life events (10 to 20 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory and other infections (10 to 30 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Surgery (2 to 12 percent)</p><p></p><p>Cases of NDPH that started with a single thunderclap headache have also been reported [<a href="#rid11">11-13</a>]. In one study, 12 out of 328 (3.6 percent) patients with NDPH had a thunderclap headache at onset [<a href="#rid9">9</a>]. It has been proposed that this syndrome might be precipitated by cerebral artery vasospasm, possibly based on a subtype of reversible cerebral vasoconstriction syndrome (RCVS) [<a href="#rid13">13</a>].</p><p>The link between NDPH and potential risk factors or inciting events such as infection, trauma, or surgery is not firmly established. An unanswered question is why the headache persists so long, even after the inciting factor has resolved. These factors may cause the headache or simply reveal an underlying predisposition to headaches in some individuals [<a href="#rid14">14</a>]. A family history of headache is present in up to 40 percent of patients with NDPH [<a href="#rid15">15</a>].</p><p>In several case series, no precipitating factor was identified in up to 80 percent of cases [<a href="#rid10">10,16</a>].</p><p class="headingAnchor" id="H3"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>When compared with other primary headache disorders, NDPH appears to be rare but widespread, as it has been described in multiple ethnic groups [<a href="#rid1">1,16</a>]. A general population study of adults in Spain found that the prevalence of NDPH was 0.1 percent, while a larger general population study of adults 30 to 44 years of age in Norway found a prevalence of 0.03 percent [<a href="#rid17">17,18</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sex</strong> – NDPH affects females more often than males. In various series, the female-to-male ratio of NDPH has ranged from 1.3 to 2.5 [<a href="#rid1">1,9,16,19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age</strong> – NDPH commonly occurs in the fourth decade of life, but the mean age of onset extends from the early teens to &gt;80 years of age [<a href="#rid1">1,9,16</a>]. In a study of 328 patients from the United States, the mean age of onset was 40.3 years old [<a href="#rid9">9</a>]. In a series from Japan of 30 patients with NDPH, the mean age of onset was 35 years [<a href="#rid16">16</a>]. The age of onset appears to be earlier among females [<a href="#rid19">19</a>]. In one report, the peak age of onset for females was in the second and third decades compared with the fifth decade for males [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1">NDPH appears to be more frequent in children than in adults. In a study of patients with chronic daily headache, the frequency of NDPH among adolescents and adults was 21 and 11 percent, respectively [<a href="#rid20">20</a>]. In reports from tertiary headache clinics of American children with chronic daily headache, the frequency of NDPH was 13 to 31 percent [<a href="#rid14">14,21-23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Temporal pattern</strong> – A seasonal pattern of onset has been described in children with NDPH. One retrospective study of 92 children in the United States found that the onset of NDPH was associated with the months that children start or return to school (September and January) [<a href="#rid24">24</a>]. However, another study of 42 children with NDPH seen in a headache center in Italy noted that 75 percent of cases began during the winter months (November to February) [<a href="#rid25">25</a>].</p><p></p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H2152633666"><span class="h2">Specific date of onset</span><span class="headingEndMark"> — </span>Unique to NDPH is the fact that the headache begins one day and typically does not remit. Up to 80 percent of patients with NDPH can pinpoint the exact date their headache started [<a href="#rid1">1</a>]. Some patients awaken from sleep with the headache, while others describe onset while awake. The headache becomes continuous and unremitting within 24 hours of onset [<a href="#rid26">26</a>].</p><p>Headache onset may correspond with or follow a triggering event, such as systemic infection or stressful life event. (See <a class="local">'Pathophysiology'</a> above.)</p><p class="headingAnchor" id="H3447713215"><span class="h2">Headache characteristics</span><span class="headingEndMark"> — </span>The phenotype of NDPH frequently resembles migraine or, less often, tension-type headache [<a href="#rid1">1,2,16,19,22,27</a>]. In a meta-analysis of 46 studies that included 2155 patients with NDPH, headaches met criteria for chronic migraine in 67 percent and tension-type headache in 33 percent [<a href="#rid15">15</a>]. Among 53 children and adolescents diagnosed with NDPH but not overusing medication at a headache clinic in the United States, most headache days (average 18.5 per month) met criteria for migraine [<a href="#rid22">22</a>].</p><p>Other headache characteristics in NDPH include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severity</strong> – The baseline average pain intensity associated with NDPH is typically moderate, although a significant proportion of patients experience severe pain all the time [<a href="#rid1">1,23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Location</strong> – The headache of NDPH is bilateral in 64 to 91 percent [<a href="#rid1">1,9,16,19</a>]. The pain can be holocranial or localized to any head region, including occipital-nuchal, temporal, and retroorbital locations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Quality</strong> – The quality of the head pain is most often throbbing and/or pressure-like. Other common descriptions include stabbing, aching, dullness, tightness, burning, and searing [<a href="#rid1">1</a>].</p><p></p><p>Headaches may be aggravated by stress, physical exertion, or bright light [<a href="#rid1">1</a>]. The course may be either self-limited or refractory. (See <a class="local">'Prognosis'</a> below.)</p><p class="headingAnchor" id="H973177683"><span class="h2">Associated features</span><span class="headingEndMark"> — </span>Nausea, vomiting, phonophobia, and photophobia may accompany the headache in NDPH [<a href="#rid21">21</a>]. In a series of 56 patients with NDPH from a referral center in the United States, associated migrainous symptoms were frequent and included nausea (68 percent), photophobia (66 percent), phonophobia (61 percent), lightheadedness (55 percent), sore/stiff neck (50 percent), blurred vision (43 percent), vomiting (23 percent), and vertigo (11 percent) [<a href="#rid1">1</a>]. In a series of 366 patients with NDPH, cranial autonomic symptoms such as miosis, lacrimation, and conjunctival injection were reported in 26 percent [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Examination</span><span class="headingEndMark"> — </span>The neurologic examination is typically normal in NDPH. Greater occipital nerve trigger point tenderness and pain with neck extension or rotation suggestive of cervical facet inflammation may be seen in some cases [<a href="#rid1">1</a>]. The significance of this finding is uncertain.</p><p class="headingAnchor" id="H7"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of NDPH is based upon the clinical features, fulfillment of diagnostic criteria  (<a class="graphic graphic_table graphicRef76010" href="/d/graphic/76010.html" rel="external">table 1</a>), and exclusion of secondary causes of headache. (See <a class="local">'Diagnostic criteria'</a> below.)</p><p>Secondary headache disorders must be excluded before making a diagnosis of NDPH [<a href="#rid29">29</a>], even in the presence of a normal neurologic examination. (See <a class="local">'Evaluation'</a> below and <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H8"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>The International Classification of Headache Disorders, 3<sup>rd</sup> edition (ICHD-3), published in 2018, describes NDPH as a persistent and continuous headache with a clearly remembered onset [<a href="#rid26">26</a>]. Headache characteristics and associated symptoms of NDPH are nonspecific and may resemble migraine or tension-type headache.</p><p>The following are the ICHD-3 diagnostic criteria for NDPH  (<a class="graphic graphic_table graphicRef76010" href="/d/graphic/76010.html" rel="external">table 1</a>) [<a href="#rid26">26</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>(A) Persistent headache fulfilling criteria B and C</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(B) Distinct and clearly remembered onset, with pain becoming continuous and unremitting within 24 hours</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(C) Present for longer than three months</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(D) Not better accounted for by another ICHD-3 diagnosis</p><p></p><p>Probable NDPH may be diagnosed for patients with headaches &lt;3 months, but who fulfill all other diagnostic criteria.</p><p>Patients with strictly unilateral chronic headaches that respond to <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> whose symptoms fulfill diagnostic criteria for both NDPH and hemicrania continua should be diagnosed with hemicrania continua [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/d/html/3342.html" rel="external">"Hemicrania continua", section on 'Diagnosis'</a>.)</p><p>Patients who present with a persistent headache without a clearly remembered onset should not be diagnosed with NDPH. Such patients should be diagnosed with another headache type, such as chronic migraine or chronic tension-type headache, based on the specific features of the headache. (See  <a class="medical medical_review" href="/d/html/3337.html" rel="external">"Chronic migraine", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/3357.html" rel="external">"Tension-type headache in adults: Etiology, clinical features, and diagnosis", section on 'Diagnosis'</a>.) </p><p class="headingAnchor" id="H9"><span class="h2">Evaluation</span><span class="headingEndMark"> — </span>New headache onset in the absence of a headache history always warrants attention. Therefore, the initial evaluation of a new and persistent daily headache must exclude secondary causes of headache.</p><p class="headingAnchor" id="H2601986276"><span class="h3">Brain imaging</span><span class="headingEndMark"> — </span>We recommend brain imaging for all patients with headache suspicious for NDPH. We typically perform brain magnetic resonance imaging (MRI) with gadolinium as the initial imaging study. Head computed tomography (CT) with contrast is an alternative for those who cannot have MRI because of intolerance, contraindications, or availability.</p><p class="headingAnchor" id="H3454113828"><span class="h3">Additional testing for patients with atypical features</span><span class="headingEndMark"> — </span>Additional evaluation may be warranted for select patients with suspected NDPH who have atypical clinical features or abnormal initial brain imaging findings suggestive of an alternative cause of the headache. Atypical features include:</p><p class="bulletIndent1"><span class="glyph">●</span>Associated abnormalities on neurologic examination (eg, cranial nerve dysfunction, vision loss, papilledema, limb weakness and/or numbness)</p><p class="bulletIndent1"><span class="glyph">●</span>Prominent associated neck pain or meningismus</p><p class="bulletIndent1"><span class="glyph">●</span>Hypercoagulable state</p><p class="bulletIndent1"><span class="glyph">●</span>Age &gt;50 years old</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal findings on brain MRI (eg, cerebral infarct, cerebral edema)</p><p class="bulletIndent1"><span class="glyph">●</span>Orthostatic headache</p><p class="bulletIndent1"><span class="glyph">●</span>Prominent worsening of headache with Valsalva-like maneuvers (eg, coughing, sneezing, bending)</p><p class="bulletIndent1"><span class="glyph">●</span>Systemic symptoms (eg, fever)</p><p></p><p>Features suggestive of an underlying cause of headache are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/3349.html" rel="external">"Evaluation of headache in adults", section on 'Specific features suggesting a secondary headache source'</a>.) </p><p>Specific testing varies according to atypical features and may include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>MRV or CTV of the head</strong> – Magnetic resonance venography (MRV) or computed tomographic venography (CTV) is indicated for patients with clinical or radiographic suspicion for cerebral venous sinus thrombosis, including patients with focal neurologic signs or venous infarction on initial brain imaging. A hypercoagulable state or signs of raised intracranial pressure (eg, papilledema) lower the threshold for obtaining MRV. (See  <a class="medical medical_review" href="/d/html/1103.html" rel="external">"Cerebral venous thrombosis: Etiology, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CTA or MRA of the head and neck</strong> – Arterial cerebrovascular imaging with head and neck magnetic resonance angiography (MRA) or computed tomography angiography (CTA) is indicated for patients who have suspected carotid or vertebral artery dissection due to the presence of Horner syndrome, focal neurologic signs, or associated neck pain. CTA or MRA is also indicated for patients who report an abrupt (ie, thunderclap) onset of a persistent headache to evaluate for the presence of cerebral vasospasm due to conditions such as aneurysmal subarachnoid hemorrhage or reversible cerebral vasoconstriction syndrome. (See  <a class="medical medical_review" href="/d/html/14082.html" rel="external">"Cerebral and cervical artery dissection: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/1130.html" rel="external">"Aneurysmal subarachnoid hemorrhage: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/14075.html" rel="external">"Reversible cerebral vasoconstriction syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lumbar puncture</strong> – Lumbar puncture for cerebrospinal fluid analysis and measurement of opening/closing pressure is indicated if there is suspicion for central nervous system infection, subarachnoid hemorrhage, or idiopathic intracranial hypertension. The threshold for a lumbar puncture is lowered in the presence of meningismus or fever or when visual symptoms and/or tinnitus are reported. (See  <a class="medical medical_review" href="/d/html/4832.html" rel="external">"Lumbar puncture: Technique, contraindications, and complications in adults", section on 'Indications'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory testing</strong> – Laboratory testing, including erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), is used to assess for giant cell arteritis (GCA) in patients over 50 years old or in those with visual disturbances or other systemic features suggestive of GCA [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/d/html/8242.html" rel="external">"Diagnosis of giant cell arteritis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spinal imaging</strong> – Spinal imaging may be indicated for patients with suspected spontaneous intracranial hypotension, including those with orthostatic headache and/or headache that worsens with Valsalva maneuvers. Initial brain MRI with gadolinium may identify abnormal findings suggestive of spontaneous intracranial hypotension but may also be normal. Further imaging to identify or exclude spontaneous intracranial hypotension may include MRI of the spine without contrast and other spinal imaging such as myelography. (See  <a class="medical medical_review" href="/d/html/3359.html" rel="external">"Spontaneous intracranial hypotension: Pathophysiology, clinical features, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H10"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Several secondary and other primary causes of headache may mimic NDPH.</p><p class="headingAnchor" id="H3737191128"><span class="h2">Secondary headache disorders</span><span class="headingEndMark"> — </span>Common secondary headache syndromes in the differential include the following [<a href="#rid31">31</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Cerebral venous sinus thrombosis</p><p class="bulletIndent1"><span class="glyph">●</span>Spontaneous intracranial hypotension due to spinal cerebrospinal fluid (CSF) leak</p><p class="bulletIndent1"><span class="glyph">●</span>Idiopathic intracranial hypertension (IIH)</p><p class="bulletIndent1"><span class="glyph">●</span>Giant cell (temporal) arteritis (GCA)</p><p></p><p class="headingAnchor" id="H11"><span class="h3">Cerebral venous sinus thrombosis</span><span class="headingEndMark"> — </span>In addition to headache, patients with cerebral venous sinus thrombosis may also have neurologic signs or symptoms, such as encephalopathy, seizures, focal weakness or numbness, cranial nerve palsies, or papilledema [<a href="#rid32">32</a>]. However, other neurologic features may be absent even in the presence of thrombus, and isolated persistent headache may be the only symptom [<a href="#rid30">30</a>]. In this setting, cerebral venous sinus thrombosis can be misdiagnosed as IIH or NDPH [<a href="#rid32">32</a>]. Brain MRI may demonstrate abnormal features suggestive of cerebral venous thrombosis, such as venous infarcts, focal cerebral edema with or without intracerebral or subarachnoid hemorrhage, and evidence of thrombus (eg, empty delta sign).</p><p>Cerebral venous thrombosis is typically identified by brain MRI in combination with magnetic resonance venography (MRV) that shows the thrombus and the occluded dural sinus or vein. (See  <a class="medical medical_review" href="/d/html/1103.html" rel="external">"Cerebral venous thrombosis: Etiology, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H12"><span class="h3">Spontaneous intracranial hypotension</span><span class="headingEndMark"> — </span>Spontaneous intracranial hypotension occurs when a spinal CSF leak leads to headache and other neurologic symptoms from brain sagging and traction on the anchoring dura. Patients with spontaneous intracranial hypotension typically report chronic, often postural headaches (ie, resolve or are significantly alleviated while lying down but recur while upright). However, some patients may present with isolated headache, and those with long-standing spontaneous intracranial hypotension may lack a postural quality to headaches. Headache exacerbation with Valsalva maneuvers (eg, coughing, sneezing) is not uncommon. Other neurologic symptoms may occur in spontaneous intracranial hypotension, such as nausea, dizziness, auditory muffling, tinnitus, and impaired gait. (See  <a class="medical medical_review" href="/d/html/3359.html" rel="external">"Spontaneous intracranial hypotension: Pathophysiology, clinical features, and diagnosis"</a>.)</p><p>Some patients who met NDPH criteria in one report were later found to have a CSF leak [<a href="#rid1">1</a>]. In another case of apparent NDPH where a thorough evaluation was negative, a CSF leak secondary to a spinal CSF-venous fistula was eventually identified [<a href="#rid33">33</a>]. Treatment of the CSF leaks in these cases led to complete headache resolution.</p><p>Spontaneous intracranial hypotension may be diagnosed by multimodal neuroimaging. Brain MRI may show diffuse pachymeningeal gadolinium thickening and enhancement and/or descent of brain within the cranial vault. Spinal MRI and/or myelography may show epidural fluid collections, collapse of the dural sac, or a dural tear. Opening CSF pressure on lumbar puncture may be low (≤60 mmH<sub>2</sub>O) or normal [<a href="#rid34">34,35</a>]. (See  <a class="medical medical_review" href="/d/html/3359.html" rel="external">"Spontaneous intracranial hypotension: Pathophysiology, clinical features, and diagnosis", section on 'Evaluation and diagnosis'</a>.)</p><p class="headingAnchor" id="H13"><span class="h3">Idiopathic intracranial hypertension</span><span class="headingEndMark"> — </span>Patients with NDPH and IIH both present with a persistent headache. Specific headache characteristics may help discriminate IIH. IIH typically presents with headache upon waking that lessens in severity as the day goes on. It is generally worse with recumbency. In addition, visual obscurations and pulsatile tinnitus may be reported. Papilledema may be seen on examination [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/d/html/5257.html" rel="external">"Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis"</a>.)</p><p>The diagnosis of IIH should be considered particularly in females of childbearing age with obesity, who account for most cases [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/d/html/5254.html" rel="external">"Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis"</a>.)</p><p>IIH is diagnosed by lumbar puncture showing elevated CSF pressure and a neuroimaging study that excludes other causes of elevated intracranial pressure. Brain MRI with and without contrast and postcontrast MRV are the imaging studies of choice. Lumbar puncture should follow MRI unless a source of elevated intracranial pressure is clearly delineated. An opening pressure greater than 250 mmH<sub>2</sub>O taken with the patient lying on the side with legs extended confirms elevated intracranial pressure. Pressures between 200 and 250 mmH<sub>2</sub>O are considered equivocal. (See  <a class="medical medical_review" href="/d/html/5257.html" rel="external">"Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H14"><span class="h3">Giant cell arteritis</span><span class="headingEndMark"> — </span>Patients with GCA may present with subacute or acute onset headache commonly associated with constitutional and other features such as fever, myalgias, jaw claudication, and visual disturbances. Laboratory testing may also demonstrate an elevated erythrocyte sedimentation rate and/or serum C-reactive protein (CRP) as well as anemia. GCA generally occurs in patients over 50 years old. Temporal artery biopsy is the gold standard for confirming the diagnosis. (See  <a class="medical medical_review" href="/d/html/8225.html" rel="external">"Clinical manifestations of giant cell arteritis"</a> and  <a class="medical medical_review" href="/d/html/8242.html" rel="external">"Diagnosis of giant cell arteritis"</a>.)</p><p class="headingAnchor" id="H3419887214"><span class="h3">Less common secondary causes</span><span class="headingEndMark"> — </span>Many other secondary headache disorders that occur acutely and persist for at least three months may also mimic NDPH. They are typically distinguished by additional clinical features, abnormalities on examination, and/or results of diagnostic testing  (<a class="graphic graphic_table graphicRef141069" href="/d/graphic/141069.html" rel="external">table 2</a>). Case reports of secondary headaches that can mimic NDPH include [<a href="#rid37">37-42</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Arteriovenous malformation</p><p class="bulletIndent1"><span class="glyph">●</span>Brain tumor</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic meningitis</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic subdural hematoma</p><p class="bulletIndent1"><span class="glyph">●</span>Dissection of carotid or vertebral artery</p><p class="bulletIndent1"><span class="glyph">●</span>Dural arteriovenous fistula</p><p class="bulletIndent1"><span class="glyph">●</span>Leptomeningeal metastasis</p><p class="bulletIndent1"><span class="glyph">●</span>Post-meningitis headache</p><p class="bulletIndent1"><span class="glyph">●</span>Post-traumatic headache</p><p class="bulletIndent1"><span class="glyph">●</span>Sphenoid sinusitis</p><p class="bulletIndent1"><span class="glyph">●</span>Subarachnoid hemorrhage</p><p class="bulletIndent1"><span class="glyph">●</span>Nutcracker syndrome</p><p></p><p class="headingAnchor" id="H15"><span class="h2">Primary headache disorders</span><span class="headingEndMark"> — </span>Other primary headache disorders may mimic NDPH [<a href="#rid22">22,27</a>]. However, although clinical features of NDPH may be similar to chronic migraine or chronic tension-type headache, NDPH is unique in that headache is daily and unremitting from, or almost from, the moment of onset, typically in individuals without a prior headache history. A clear recall of such an onset is necessary for the diagnosis of NDPH [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/d/html/3337.html" rel="external">"Chronic migraine"</a> and  <a class="medical medical_review" href="/d/html/3357.html" rel="external">"Tension-type headache in adults: Etiology, clinical features, and diagnosis"</a>.)</p><p>If headaches are strictly unilateral, hemicrania continua may be a more likely diagnosis than NDPH. A trial of <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> can be both diagnostic and therapeutic in this setting. (See  <a class="medical medical_review" href="/d/html/3342.html" rel="external">"Hemicrania continua"</a>.)</p><p class="headingAnchor" id="H2679458357"><span class="h2">Medication overuse headache</span><span class="headingEndMark"> — </span>The combination of daily headaches and the frequent use of medication for acute headache treatment may create diagnostic uncertainty because ongoing headaches may be due to the inciting headache condition, medication overuse headache, or both. The temporal relationship between headache onset and the development of daily headache immediately after onset is more suggestive of NDPH, while intermittent headache attacks that progress to daily headaches after frequent use of medications such as opioids, triptans, or combination analgesics is more suggestive of medication overuse headaches [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/d/html/3340.html" rel="external">"Medication overuse headache: Etiology, clinical features, and diagnosis"</a>.)</p><p>However, NDPH and medication overuse headache can be comorbid. Patients with NDPH may be overusing analgesics by the time they are seen in clinic [<a href="#rid30">30</a>]. In a series of 245 children with NDPH, approximately one-third were also diagnosed with medication overuse headache [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H17"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H2541929573"><span class="h2">Initial treatment approach</span><span class="headingEndMark"> — </span>Our initial treatment approach for NDPH begins by classifying the phenotype of NDPH. The phenotype of NDPH often resembles primary chronic tension-type headache or chronic migraine (see <a class="local">'Headache characteristics'</a> above). We then treat with appropriate preventive headache therapy accordingly [<a href="#rid36">36,43</a>]. The selection of a specific agent should be individualized based on risk factors and the presence of comorbid conditions.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3337.html" rel="external">"Chronic migraine", section on 'Management'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3360.html" rel="external">"Tension-type headache in adults: Preventive treatment"</a>.)</p><p></p><p>In addition, analgesic overuse should be stopped if concurrent with NDPH, even though available evidence suggests that medication withdrawal typically does not help relieve the pain in NDPH [<a href="#rid30">30</a>]. This contrasts with the improvement that often occurs with drug withdrawal in patients who have background migraine and medication overuse headache. (See  <a class="medical medical_review" href="/d/html/3341.html" rel="external">"Medication overuse headache: Treatment and prognosis"</a>.)</p><p>Some reports suggest the response rate to pharmacologic treatment is better early in the course of NDPH (eg, during the first year) compared with late (eg, at 10 to 20 years) [<a href="#rid30">30</a>]. However, this relationship has not been demonstrated in all studies [<a href="#rid16">16,44</a>].</p><p>Phenotype-based treatment for NDPH is based on case series and expert opinion as high-quality evidence of efficacy is lacking [<a href="#rid43">43</a>]. Data regarding the effectiveness of specific treatments for primary NDPH are limited to small series and case reports. In one report, 30 patients with NDPH were treated for five years, beginning with muscle relaxants (<a class="drug drug_general" data-topicid="9999" href="/d/drug information/9999.html" rel="external">tizanidine</a> or <a class="drug drug_general" data-topicid="9062" href="/d/drug information/9062.html" rel="external">baclofen</a>) [<a href="#rid16">16</a>]. Patients who did not respond were subsequently treated with <a class="drug drug_general" data-topicid="8605" href="/d/drug information/8605.html" rel="external">amitriptyline</a>, serotonin-specific reuptake inhibitors (<a class="drug drug_general" data-topicid="8474" href="/d/drug information/8474.html" rel="external">fluvoxamine</a> or <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a>), and/or <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproic acid</a>. By self-assessment, the outcome was considered very effective in 27 percent, moderately effective in 3 percent, mildly effective in 20 percent, and not effective in 50 percent. In another report of 162 patients with NDPH treated with various preventive therapies, agents with the highest reported response rates were methysergide (28 percent), <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a> (23 percent), amitriptyline (19 percent), and <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> (19 percent) [<a href="#rid27">27</a>]. A short course of <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> was reported to be effective in a small series of nine patients with presumed NDPH of recent onset (duration three to five weeks) [<a href="#rid44">44</a>]. Some headache experts have reported successful therapy of NDPH with other agents that are effective for tension-type headaches and/or migraine headache including <a class="drug drug_general" data-topicid="9711" href="/d/drug information/9711.html" rel="external">nortriptyline</a>, <a class="drug drug_general" data-topicid="8940" href="/d/drug information/8940.html" rel="external">atenolol</a>, <a class="drug drug_general" data-topicid="9656" href="/d/drug information/9656.html" rel="external">mirtazapine</a>, and <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a> [<a href="#rid30">30,36,45-47</a>].</p><p class="headingAnchor" id="H3462286704"><span class="h2">Patients with refractory symptoms</span><span class="headingEndMark"> — </span>For patients whose symptoms do not respond to initial treatment, we switch to an alternative agent from a different pharmacologic class. A second agent can be added for patients with a partial response to initial treatment.</p><p>Limited data suggest NDPH symptoms may respond to <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>, <a class="drug drug_general" data-topicid="117927" href="/d/drug information/117927.html" rel="external">erenumab</a>, or peripheral nerve blocks [<a href="#rid48">48-50</a>]. In a small series of 16 patients with NDPH who received <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> every three months, symptoms improved in 50 and 78 percent of patients at 6 and 12 months, respectively [<a href="#rid51">51</a>]. Other authors have anecdotally seen benefit using nonsteroidal antiinflammatory drugs combined with muscle relaxants and neck physical therapy [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H3915875740"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>NDPH appears to have two subtypes: a self-limited form that typically resolves without therapy within several months and a refractory form that is resistant to aggressive treatment regimens [<a href="#rid26">26,30,52</a>]. Very likely, the refractory form is the one seen in the clinician's office. Self-limited forms may not reach medical attention.</p><p>The original report describing NDPH with 45 patients (19 male, 26 female) found that, at two years from onset, 16 males (84 percent) and 19 females (73 percent) were headache-free without treatment [<a href="#rid19">19</a>]. In a later series of 18 cases, the number of patients pain-free at two years after headache onset was 12 (66 percent) [<a href="#rid2">2</a>].</p><p>However, in other studies and in practice, NDPH can endure for many years or even decades and be completely refractory to treatment [<a href="#rid16">16,30</a>]. Many headache specialists consider NDPH to be the most treatment refractory of all headache disorders. In a series of 56 patients, all patients at study entry had NDPH for at least six months, many had headache for more than five years, and a few had headache for more than 10 years [<a href="#rid1">1</a>]. In a retrospective series of 328 patients, the median duration of NDPH at last visit was 1.9 years, and prognostic types were persisting/refractory in 93.0 percent, relapsing-remitting in 2.7 percent, and remitting or self-limited in 4.3 percent [<a href="#rid9">9</a>].</p><p>The true long-term prognosis of refractory NDPH is unknown [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H2939554993"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110285.html" rel="external">"Society guideline links: Migraine and other primary headache disorders"</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and epidemiology</strong> – NDPH is a primary headache disorder in which headache begins one day and does not remit, usually in an individual without a headache history. NDPH may occur spontaneously or after a systemic trigger such as infection or stressful life event. The condition appears to be rare, with a general population prevalence that is likely less than 0.1 percent. Available evidence suggests that NDPH is more frequent in children than in adults and affects females more often than males. (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – NDPH is characterized by a new-onset headache that starts rather abruptly and becomes continuous and unremitting within 24 hours of onset. The pain in NDPH lacks specific features and may be migraine-like, tension type–like, or have elements of both. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of NDPH is based upon the clinical features, fulfillment of diagnostic criteria  (<a class="graphic graphic_table graphicRef76010" href="/d/graphic/76010.html" rel="external">table 1</a>), and exclusion of secondary causes of headache. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – For all patients with NDPH, we recommend brain MRI with contrast upon presentation. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1">Additional evaluation may be warranted for select patients with suspected NDPH who have atypical clinical features or abnormal initial brain imaging findings suggestive of an alternative diagnosis. Specific testing varies according to atypical features and may include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Magnetic resonance (MR) venography or computed tomographic (CT) venography of the head</p><p class="bulletIndent2"><span class="glyph">•</span>CT angiography or MR angiography of the head and neck</p><p class="bulletIndent2"><span class="glyph">•</span>Lumbar puncture cerebrospinal fluid (CSF) analysis</p><p class="bulletIndent2"><span class="glyph">•</span>Laboratory testing such as erythrocyte sedimentation rate and C-reactive protein (CRP)</p><p class="bulletIndent2"><span class="glyph">•</span>Spinal imaging such as MRI with contrast and/or myelography</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis of NDPH includes several secondary and primary causes of headache. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Common secondary causes to symptoms include cerebral venous sinus thrombosis, spontaneous intracranial hypotension from spinal cerebrospinal fluid leaks, idiopathic intracranial hypertension (IIH), and giant cell arteritis (GCA). (See <a class="local">'Secondary headache disorders'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Primary headache that may mimic NDPH include chronic migraine, tension-type headache, and hemicrania continua. (See <a class="local">'Differential diagnosis'</a> above and <a class="local">'Primary headache disorders'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Medication overuse headache may mimic NDPH but can also be a comorbid condition when refractory NDPH symptoms lead to medication overuse. (See <a class="local">'Medication overuse headache'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – For patients with NDPH, we suggest treating with a preventive medication according to the headache phenotype (eg, migraine, tension-type) that best aligns with the clinical syndrome of the patient (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Phenotype-based treatment for NDPH is based on case series and expert opinion. The selection of a specific agent should be individualized based on risk factors and the presence of comorbid conditions. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1">For patients whose symptoms do not respond to initial treatment, we switch to an alternative agent from a different pharmacologic class. A second agent can be added for patients with a partial response to initial treatment. Options include <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>, <a class="drug drug_general" data-topicid="117927" href="/d/drug information/117927.html" rel="external">erenumab</a>, peripheral nerve blocks, or botulinum toxin injections.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – NDPH may take either of two subtypes: a self-limited one or a persistent form, which can last years or decades and is challenging to treat. (See <a class="local">'Prognosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Li D, Rozen TD. The clinical characteristics of new daily persistent headache. Cephalalgia 2002; 22:66.</a></li><li><a class="nounderline abstract_t">Meineri P, Torre E, Rota E, Grasso E. New daily persistent headache: clinical and serological characteristics in a retrospective study. Neurol Sci 2004; 25 Suppl 3:S281.</a></li><li><a class="nounderline abstract_t">de Abreu LV, Oliveira CB, Bordini CA, Valença MM. New Daily Persistent Headache Following Dengue Fever: Report of Three Cases and an Epidemiological Study. Headache 2020; 60:265.</a></li><li><a class="nounderline abstract_t">Simmons AC, Bonner A, Giel A, et al. Probable New Daily Persistent Headache After COVID-19 in Children and Adolescents. Pediatr Neurol 2022; 132:1.</a></li><li><a class="nounderline abstract_t">Torrente A, Alonge P, Di Stefano V, et al. New-onset headache following COVID-19: An Italian multicentre case series. J Neurol Sci 2023; 446:120591.</a></li><li><a class="nounderline abstract_t">Sampaio Rocha-Filho PA. Headache associated with COVID-19: Epidemiology, characteristics, pathophysiology, and management. Headache 2022; 62:650.</a></li><li><a class="nounderline abstract_t">Diaz-Mitoma F, Vanast WJ, Tyrrell DL. Increased frequency of Epstein-Barr virus excretion in patients with new daily persistent headaches. Lancet 1987; 1:411.</a></li><li><a class="nounderline abstract_t">Evans RW, Rozen TD. Etiology and treatment of new daily persistent headache. Headache 2001; 41:830.</a></li><li><a class="nounderline abstract_t">Evans RW, Turner DP. Clinical features of new daily persistent headache: A retrospective chart review of 328 cases. Headache 2021; 61:1529.</a></li><li><a class="nounderline abstract_t">Rozen TD. Triggering Events and New Daily Persistent Headache: Age and Gender Differences and Insights on Pathogenesis-A Clinic-Based Study. Headache 2016; 56:164.</a></li><li><a class="nounderline abstract_t">Robbins MS, Evans RW. The heterogeneity of new daily persistent headache. Headache 2012; 52:1579.</a></li><li><a class="nounderline abstract_t">Rozen TD, Beams JL. New daily persistent headache with a thunderclap headache onset and complete response to nimodipine (a new distinct subtype of NDPH). J Headache Pain 2013; 14:100.</a></li><li><a class="nounderline abstract_t">Jamali SA, Rozen TD. An RCVS Spectrum Disorder? New Daily Persistent Headache Starting as a Single Thunderclap Headache (3 New Cases). Headache 2019; 59:789.</a></li><li><a class="nounderline abstract_t">Mack KJ. What incites new daily persistent headache in children? Pediatr Neurol 2004; 31:122.</a></li><li><a class="nounderline abstract_t">Cheema S, Mehta D, Ray JC, et al. New daily persistent headache: A systematic review and meta-analysis. Cephalalgia 2023; 43:3331024231168089.</a></li><li><a class="nounderline abstract_t">Takase Y, Nakano M, Tatsumi C, Matsuyama T. Clinical features, effectiveness of drug-based treatment, and prognosis of new daily persistent headache (NDPH): 30 cases in Japan. Cephalalgia 2004; 24:955.</a></li><li><a class="nounderline abstract_t">Castillo J, Muñoz P, Guitera V, Pascual J. Kaplan Award 1998. Epidemiology of chronic daily headache in the general population. Headache 1999; 39:190.</a></li><li><a class="nounderline abstract_t">Grande RB, Aaseth K, Lundqvist C, Russell MB. Prevalence of new daily persistent headache in the general population. The Akershus study of chronic headache. Cephalalgia 2009; 29:1149.</a></li><li><a class="nounderline abstract_t">Vanast WJ. New daily persistent headaches: definition of a benign syndrome. Headache 1986; 26:317.</a></li><li><a class="nounderline abstract_t">Bigal ME, Lipton RB, Tepper SJ, et al. Primary chronic daily headache and its subtypes in adolescents and adults. Neurology 2004; 63:843.</a></li><li><a class="nounderline abstract_t">Strong E, Pierce EL, Langdon R, et al. New Daily Persistent Headache in a Pediatric Population. J Child Neurol 2021; 36:888.</a></li><li><a class="nounderline abstract_t">Kung E, Tepper SJ, Rapoport AM, et al. New daily persistent headache in the paediatric population. Cephalalgia 2009; 29:17.</a></li><li><a class="nounderline abstract_t">Reidy BL, Riddle EJ, Powers SW, et al. Clinic-based characterization of continuous headache in children and adolescents: Comparing youth with chronic migraine to those with new daily persistent headache. Cephalalgia 2020; 40:1063.</a></li><li><a class="nounderline abstract_t">Grengs LR, Mack KJ. New Daily Persistent Headache Is Most Likely to Begin at the Start of School. J Child Neurol 2016; 31:864.</a></li><li><a class="nounderline abstract_t">Papetti L, Sforza G, Tarantino S, et al. Features and Management of New Daily Persistent Headache in Developmental-Age Patients. Diagnostics (Basel) 2021; 11.</a></li><li><a class="nounderline abstract_t">Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38:1.</a></li><li><a class="nounderline abstract_t">Lobo R, Wang M, Lobo S, Bahra A. Time to retire 'New daily persistent headache': Mode of onset of chronic migraine and tension-type headache. Cephalalgia 2022; 42:385.</a></li><li><a class="nounderline abstract_t">Cheema S, Stubberud A, Rantell K, et al. Phenotype of new daily persistent headache: subtypes and comparison to transformed chronic daily headache. J Headache Pain 2023; 24:109.</a></li><li><a class="nounderline abstract_t">Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.</a></li><li><a class="nounderline abstract_t">Rozen TD. New daily persistent headache. Curr Pain Headache Rep 2003; 7:218.</a></li><li><a class="nounderline abstract_t">Rozen TD. New daily persistent headache: clinical perspective. Headache 2011; 51:641.</a></li><li><a class="nounderline abstract_t">Evans RW. New daily persistent headache. Curr Pain Headache Rep 2003; 7:303.</a></li><li><a class="nounderline abstract_t">Duvall JR, Robertson CE, Whealy MA, Garza I. Clinical Reasoning: An underrecognized etiology of new daily persistent headache. Neurology 2020; 94:e114.</a></li><li><a class="nounderline abstract_t">Duvall JR, Robertson CE, Cutsforth-Gregory JK, et al. Headache due to spontaneous spinal cerebrospinal fluid leak secondary to cerebrospinal fluid-venous fistula: Case series. Cephalalgia 2019; 39:1847.</a></li><li><a class="nounderline abstract_t">Kranz PG, Tanpitukpongse TP, Choudhury KR, et al. How common is normal cerebrospinal fluid pressure in spontaneous intracranial hypotension? Cephalalgia 2015.</a></li><li><a class="nounderline abstract_t">Goadsby PJ, Boes C. New daily persistent headache. J Neurol Neurosurg Psychiatry 2002; 72 Suppl 2:ii6.</a></li><li><a class="nounderline abstract_t">Rozen TD, Devcic Z, Toskich B, et al. Nutcracker phenomenon with a daily persistent headache as the primary symptom: Case series and a proposed pathogenesis model based on a novel MRI technique to evaluate for spinal epidural venous congestion. J Neurol Sci 2022; 434:120170.</a></li><li><a class="nounderline abstract_t">Devcic Z, Rozen TD, Arora M, et al. Daily persistent headache with nutcracker physiology and spinal epidural venous congestion: Treatment with lumbar vein embolization. Radiol Case Rep 2022; 17:4314.</a></li><li><a class="nounderline abstract_t">Garza I. Images from headache: a "noisy" headache: dural arteriovenous fistula resembling new daily persistent headache. Headache 2008; 48:1120.</a></li><li><a class="nounderline abstract_t">Evans RW. New daily persistent headache. Headache 2012; 52 Suppl 1:40.</a></li><li><a class="nounderline abstract_t">Ogunlaja O, Zhang N. New Daily Persistent Headache Syndrome Secondary to Clival Metastasis Within an Osseous Hemangioma. Headache 2019; 59:1609.</a></li><li><a class="nounderline abstract_t">Patterson Gentile C, Aguirre GK, Hershey AD, Szperka CL. Comparison of continuous headache features in youth with migraine, new daily persistent headache, and persistent post-traumatic headache. Cephalalgia 2023; 43:3331024221131331.</a></li><li><a class="nounderline abstract_t">Yamani N, Olesen J. New daily persistent headache: a systematic review on an enigmatic disorder. J Headache Pain 2019; 20:80.</a></li><li><a class="nounderline abstract_t">Prakash S, Shah ND. Post-infectious new daily persistent headache may respond to intravenous methylprednisolone. J Headache Pain 2010; 11:59.</a></li><li><a class="nounderline abstract_t">Mack KJ. New daily persistent headache in children and adults. Curr Pain Headache Rep 2009; 13:47.</a></li><li><a class="nounderline abstract_t">Smith JH. Mirtazapine for new daily persistent headache-associated chronic nausea. Headache 2015; 55:176.</a></li><li><a class="nounderline abstract_t">Tariq Z, Board N, Eftimiades A, Ibrahim R. Resolution of new daily persistent headache by a tumor necrosis factor alpha antagonist, Venlafaxine. SAGE Open Med Case Rep 2019; 7:2050313X19847804.</a></li><li><a class="nounderline abstract_t">Puledda F, Goadsby PJ, Prabhakar P. Treatment of disabling headache with greater occipital nerve injections in a large population of childhood and adolescent patients: a service evaluation. J Headache Pain 2018; 19:5.</a></li><li><a class="nounderline abstract_t">Hascalovici JR, Robbins MS. Peripheral Nerve Blocks for the Treatment of Headache in Older Adults: A Retrospective Study. Headache 2017; 57:80.</a></li><li><a class="nounderline abstract_t">Buture A, Tomkins EM, Shukralla A, et al. Two-year, real-world erenumab persistence and quality of life data in 82 pooled patients with abrupt onset, unremitting, treatment refractory headache and a migraine phenotype: New daily persistent headache or persistent post-traumatic headache in the majority of cases. Cephalalgia 2023; 43:3331024231182126.</a></li><li><a class="nounderline abstract_t">Ali A, Kriegler J, Tepper S, Vij B. New Daily Persistent Headache and OnabotulinumtoxinA Therapy. Clin Neuropharmacol 2019; 42:1.</a></li><li><a class="nounderline abstract_t">Robbins MS, Grosberg BM, Napchan U, et al. Clinical and prognostic subforms of new daily-persistent headache. Neurology 2010; 74:1358.</a></li></ol></div><div id="topicVersionRevision">Topic 3343 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11993616" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The clinical characteristics of new daily persistent headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15549561" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : New daily persistent headache: clinical and serological characteristics in a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31883109" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : New Daily Persistent Headache Following Dengue Fever: Report of Three Cases and an Epidemiological Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35598584" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Probable New Daily Persistent Headache After COVID-19 in Children and Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36807975" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : New-onset headache following COVID-19: An Italian multicentre case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35545780" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Headache associated with COVID-19: Epidemiology, characteristics, pathophysiology, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2880216" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Increased frequency of Epstein-Barr virus excretion in patients with new daily persistent headaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11576211" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Etiology and treatment of new daily persistent headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34710236" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical features of new daily persistent headache: A retrospective chart review of 328 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26474179" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Triggering Events and New Daily Persistent Headache: Age and Gender Differences and Insights on Pathogenesis-A Clinic-Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23078412" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The heterogeneity of new daily persistent headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24364890" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : New daily persistent headache with a thunderclap headache onset and complete response to nimodipine (a new distinct subtype of NDPH).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30830966" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : An RCVS Spectrum Disorder? New Daily Persistent Headache Starting as a Single Thunderclap Headache (3 New Cases).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15301832" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : What incites new daily persistent headache in children?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37032616" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : New daily persistent headache: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15482358" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Clinical features, effectiveness of drug-based treatment, and prognosis of new daily persistent headache (NDPH): 30 cases in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15613213" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Kaplan Award 1998. Epidemiology of chronic daily headache in the general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19830882" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Prevalence of new daily persistent headache in the general population. The Akershus study of chronic headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : New daily persistent headaches: definition of a benign syndrome</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15365134" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Primary chronic daily headache and its subtypes in adolescents and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34048280" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : New Daily Persistent Headache in a Pediatric Population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19126116" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : New daily persistent headache in the paediatric population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32336121" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Clinic-based characterization of continuous headache in children and adolescents: Comparing youth with chronic migraine to those with new daily persistent headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26733504" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : New Daily Persistent Headache Is Most Likely to Begin at the Start of School.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33668316" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Features and Management of New Daily Persistent Headache in Developmental-Age Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29368949" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34579562" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Time to retire 'New daily persistent headache': Mode of onset of chronic migraine and tension-type headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37587430" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Phenotype of new daily persistent headache: subtypes and comparison to transformed chronic daily headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14979299" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The International Classification of Headache Disorders: 2nd edition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12720602" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : New daily persistent headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21457251" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : New daily persistent headache: clinical perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12828880" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : New daily persistent headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31889019" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Clinical Reasoning: An underrecognized etiology of new daily persistent headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31597463" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Headache due to spontaneous spinal cerebrospinal fluid leak secondary to cerebrospinal fluid-venous fistula: Case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26682575" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : How common is normal cerebrospinal fluid pressure in spontaneous intracranial hypotension?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12122194" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : New daily persistent headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35093724" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Nutcracker phenomenon with a daily persistent headache as the primary symptom: Case series and a proposed pathogenesis model based on a novel MRI technique to evaluate for spinal epidural venous congestion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36132058" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Daily persistent headache with nutcracker physiology and spinal epidural venous congestion: Treatment with lumbar vein embolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18547267" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Images from headache: a "noisy" headache: dural arteriovenous fistula resembling new daily persistent headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22540206" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : New daily persistent headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31535364" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : New Daily Persistent Headache Syndrome Secondary to Clival Metastasis Within an Osseous Hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36587297" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Comparison of continuous headache features in youth with migraine, new daily persistent headache, and persistent post-traumatic headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31307396" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : New daily persistent headache: a systematic review on an enigmatic disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19936615" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Post-infectious new daily persistent headache may respond to intravenous methylprednisolone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19126371" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : New daily persistent headache in children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25262618" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Mirtazapine for new daily persistent headache-associated chronic nausea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31105954" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Resolution of new daily persistent headache by a tumor necrosis factor alpha antagonist, Venlafaxine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29340791" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Treatment of disabling headache with greater occipital nerve injections in a large population of childhood and adolescent patients: a service evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27901275" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Peripheral Nerve Blocks for the Treatment of Headache in Older Adults: A Retrospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37317535" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Two-year, real-world erenumab persistence and quality of life data in 82 pooled patients with abrupt onset, unremitting, treatment refractory headache and a migraine phenotype: New daily persistent headache or persistent post-traumatic headache in the majority of cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30499777" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : New Daily Persistent Headache and OnabotulinumtoxinA Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20421580" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Clinical and prognostic subforms of new daily-persistent headache.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
